ENTA Enanta Pharmaceuticals Inc.

42.71
-1.14  -3%
Previous Close 43.85
Open 43.60
Price To book 3.13
Market Cap 815350258
Shares 19,090,383
Volume 140,067
Short Ratio 5.45
Av. Daily Volume 189,093

SEC filingsSee all SEC filings

  1. 8-K - Current report 171082270
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171017911
  3. 8-K - Current report 171011655
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 17830160
  5. 8-K/A [Amend] - Current report 17826400

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to commence 4Q 2017.
EDP-305
Non-alcoholic steatohepatitis (NASH) with cirrhosis
Phase 2 trial to commence 4Q 2017.
EDP-305
Primary biliary cholangitis (PBC)
Priority review granted February 2, 2017. No PDUFA date supplied. Estimate August 2, 2017.
Glecaprevir/Pibrentasvir (G/P)
Hepatitis C virus (HCV)
Phase 2b ongoing. Data released November 2015. Phase 3 initiated
ABT-493
HCV
Approved December 19, 2014.
VIEKIRA PAK
HCV - genotype 1
Approved July 25, 2017.
VIEKIRA PAK - once-daily, fixed-dose formulation through Abbvie
HCV - genotype

Latest News

  1. ETFs with exposure to Enanta Pharmaceuticals, Inc. : September 19, 2017
  2. Enanta Pharmaceuticals, Inc. :ENTA-US: Earnings Analysis: Q3, 2017 By the Numbers : September 18, 2017
  3. Enanta Pharmaceuticals Announces the Appointment of Kristine Peterson to Its Board of Directors
  4. Enanta Pharmaceuticals to Present at Three Upcoming Investor Conferences
  5. Enanta Pharmaceuticals (ENTA) Looks Good: Stock Adds 9.6% in Session
  6. Surging Earnings Estimates Signal Good News for Enanta Pharmaceuticals (ENTA)
  7. AbbVie's MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes
  8. Edited Transcript of ENTA earnings conference call or presentation 7-Aug-17 8:30pm GMT
  9. Enanta Pharmaceuticals reports 3Q loss
  10. Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2017
  11. Investor Network: Enanta Pharmaceuticals, Inc. to Host Earnings Call
  12. Zacks.com featured highlights: Columbus McKinnon, The New York Times, Advanced Accelerator Applications, Enanta Pharmaceuticals and Caesars Entertainment
  13. Enanta Announces U.S. FDA Approval of AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in as Little as 8 Weeks
  14. Buy These 5 Stocks on New Analyst Coverage
  15. Featured Company News – EC Grants AbbVie's MAVIRET Marketing Authorization for Treatment of Chronic Hepatitis C
  16. Enanta Announces European Commission Grants AbbVie Marketing Authorization for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
  17. European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
  18. 4 Drug Stocks in Focus this World Hepatitis Day
  19. Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Third Quarter Ended June 30, 2017
  20. ETFs with exposure to Enanta Pharmaceuticals, Inc. : July 11, 2017

SEC Filings

  1. 8-K - Current report 171082270
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171017911
  3. 8-K - Current report 171011655
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 17830160
  5. 8-K/A [Amend] - Current report 17826400
  6. 8-K - Current report 17822172
  7. 8-K - Current report 17625068
  8. SC 13G - Statement of acquisition of beneficial ownership by individuals 17613698
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 17587596
  10. 8-K - Current report 17582691